and STEP-HFpEF DM trials. Included were patients with a history of heart failure with preserved ejection fraction (HFpEF), obesity, type 2 diabetes, and cardiovascular disease. Altogether, 3743 ...

Once-weekly semaglutide (Wegovy; Novo Nordisk) improves outcomes in patients who have obesity-related heart failure with preserved ejection fraction (HFpEF) across subgroups defined by baseline ...

At baseline, HF affected 19.4% of the semaglutide group and 19.0% of the placebo group. Among those with HF history, 47.9% had preserved ejection fraction (HFpEF), 18.1% had reduced ejection fraction ...

A prespecified analysis of the FLOW trial demonstrates the benefit of semaglutide in reducing the composite risk of heart failure events ... ejection fraction (HFpEF), 18.1% had reduced ejection ...

As communicated earlier this year, Novo Nordisk will resubmit to the US Food & Drug Administration for inclusion of data from the STEP HFpEF trials in the Wegovy ® label in the US in 2025. 1) ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

In both trials, Wegovy demonstrated greater reductions in heart failure-related symptoms and greater improvements ... The primary objective of STEP HFpEF and STEP HFpEF-DM trials was to investigate ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure ... Novo Nordisk's STEP-HFpEF study of semaglutide is that ...